Update on the clinical development of candidate malaria vaccines

American Journal of Tropical Medicine and Hygiene

Volumn 71, Issue 2 SUPPL., 2004, Pages 239-247

  Ballou, W Ripley ^a   Arevalo Herrera, Myriam ^b   Carucci, Daniel ^c   Richie, Thomas L ^c   Corradin, Giampietro ^d   Diggs, Carter ^e   Druilhe, Pierre ^f   Giersing, Birgitte K ^g   Saul, Allan ^g   Heppner, D Gray ^h   Kester, Kent E ^h   Lanar, David E ^h   Lyon, Jeff ^h   Hill, Adrian V S ⁱ   Pan, Weiqing ^j   Cohen, Joe D ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b Malaria Vacc and Drug Test Center   (Colombia)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^f INSTITUT PASTEUR   (France)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j SECOND MILITARY MEDICAL UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; FALCIPARUM MEROZOITE PROTEIN 1; GLUTAMATE RICH PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; ICC 1132; IMMUNOLOGICAL ADJUVANT; LIPOPEPTIDE; LIVER STAGE ANTIGEN 1; LIVER STAGE ANTIGEN 3; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; PFS25 ANTIGEN; PLASMID DNA; PROTEIN; PROTOZOAL PROTEIN; PVS25 ANTIGEN; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; THROMBOSPONDIN; THROMBOSPONDIN RELATED ADHESIVE PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HUMAN; IMMUNOGENICITY; MOUSE; NONHUMAN; SIDE EFFECT;

PROTOZOA;

EID: 4344688712     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2004.71.239     Document Type: Conference Paper

References (36)

1. Nussenzweig RS, Vanderberg J, Most H, Orton C, 1967. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216: 160-162.
2. Huffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedagah M, Heppner DG, Ballou WR, Richie TL, 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155-1164.
3. Nevill CG, Some ES, Mung'ala VO, Mutemi W, New L, Marsh K, Lengeler C, Snow RW, 1996. Insecticide-treated bednets reduce mortality and severe morbidity from malaria among children on the Kenyan coast. Trop Med Int Health 1: 139-146.
4. Bojang KA, Milligan PJM, Finder M, Vigneron L, Alloueche A. Kester KE, Ballou WR, Conway DJ, Reece WHH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill AVS, McAdam KPWJ, Tornieporth N, Cohen JD, Doherty T, 2001. Efficacy of RTS,S/AS02A malaria vaccine against Plasmodium falcipanim infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358: 1927-1934.
5. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, Gordon DM, Schneider I, Wirtz RA, Young JF, Wasserman GF, Reeve P, Diggs CL, Chulay JD, 1987. Safety and efficacy of a recombinant DNA Plasmodium falcipanim sporozoite vaccine. Lancet 1: 1277-1281.
6. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG, Yuan G, Hollingdale M, Slaoui M, Hauser P, Voet P, Sadoff JC, Ballou WR, 1995. Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171: 1576-1585.
7. Stoute JA, Slaoui M, Heppner DG, Momin P, Rester KE, Desmons P, Wellde BT, Garçon N, Krzych U, Marchand M, Ballou WR, Cohen JD, 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 336: 86-91.
8. Garcon N, Heppner DG, Cohen J, 2003. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2: 231-238.
9. Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M. Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AVS, Cohen J, 1999. Potent induction of Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 180: 1656-1664.
10. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MS, Palensky J, Wittes J, Cohen J, Ballou WR; RTS,S Malaria Vaccine Evaluation Group, 2001. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183: 640-647.
11. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, Glenn G, Ockenhouse CF, Garcon N, Schwenk R, Lanar DE, Sun P, Momin P, Wirtz RA, Golenda C, Slaoui M, Wortmann G, Holland C, Dowler M, Cohen J, Ballou WR, 1998. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 178: 1139-1144.
12. Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, Ballou WR, Holland CA, Kester KE, Voss G, Momin P, Greenwood BM, McAdam KP, Cohen J, 1999. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am J Trop Med Hyg 61: 865-868.
13. Birkett A, Lyons K, Schmidt A, Boyd D, Oliveira GA, Siddique A, Nussenzweig R, Calvo-Calle JM, Nardin E, 2002. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 70: 6860-6870.
14. Milich DR, Hughes J, Jones J, Sallberg M, Phillips TR, 2002. Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. Vaccine 20: 771-778.
15. + T lymphocyte immune response in humans. Implications for vaccination strategies. Eur J Immunol 31: 1989-1998.
16. Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, BenMohamed L, Slierendregt B, Eling W, Van Belkum A, Dubreuil G, Meis JF, Guerin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P, Mohamed LB, 2000. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 6: 1258-1263.
17. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus. Ankara. Nat Med 4: 397-402.
18. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV, 2003. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735.
19. Moorthy VS, Finder M, Reece WH, Watkins K, Atabani S, Hannan C, Bojang K, McAdam KP, Schneider J, Gilbert S, Hill AV, 2003. Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J Infect Dis 188: 1239-1244.
20. Wang R, Doolan DL, Charoenvit Y, Hedstrom RC, Gardner MJ, Hobart P, Tine J, Sedegah M, Fallarme V, Sacci JB Jr, Kaur M, Klinman DM, Huffman SL, Weiss WR, 1998. Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids. Infect Immun 66: 4193-4202.
21. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Huffman SL, 2000. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18: 1893-1901.
22. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR, Sedegah M, de Taisne C, Norman JA, Hoffman SL, 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282: 476-480.
23. Arevalo-Herrera M, Valencia AZ, Vergara J, Bonelo A, Fleischhauer K, Gonzalez JM, Restrepo JC, Lopez JA, Valmori D, Corradin G, Herrera S, 2002. Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunol 24: 161-169.
24. Good MF, 2001. Towards a blood-stage vaccine for malaria: are we following all the leads? Nat Rev Immunol 1: 117-125.
25. Holder AA, Guevara Patino JA, Uthaipibull C, Syed SE, Ling IT, Scott-Finnigan T, Blackman MJ, 1999. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parasitologia 41: 409-414.
26. Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA, 2003. Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-1(42) malaria vaccine. Mol Biochem Parasitol 128: 195-204.
27. Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, Tam LQ, Hashiro CQ, Nikaido CM, Gibson HL, Lee-Ng CT, Barr PJ, Yokota BT, Hut GS, 1996. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun 64: 253-261.
28. Garraud O, Diouf A, Nguer CM, Dieye A, Longacre S, Kaslow DC, Holder AA, Tall A, Molez JF, Perraut R, Mercereau-Puijalon O, 1999. Different Plasmodium falciparum recombinant MSP1(19) antigens differ in their capacities to stimulate in vitro peripheral blood T lymphocytes in individuals from various endemic areas. Scand J Immunol 49: 431-440.
29. Pan W, Ravot E, Tolle R, Frank R, Mosbach R, Turbachova I, Bujard H, 1999. Vaccine candidate MSP-1 from Plasmodium falciparum: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells. Nucleic Acids Res 27: 1094-1103.
30. Hodder AN, Crewther PE, Anders RF, 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69: 3286-3294.
31. Anders RF, Crewther PE, Edwards S, Margetts M, Matthew ML, Pollock B, Pye D, 1998. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16: 240-247.
32. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW, 2002. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70: 6948-6960.
33. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P, 1994. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84: 1594-1602.
34. Oeuvray C. Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P, 2000. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 68: 2617-2620.
35. Gozar MM, Muratova O, Keister DB, Kensil CR, Price VL, Kaslow DC, 2001. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. Exp Parasitol 97: 61-69.
36. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP, 2002. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185: 820-827.